These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36198539)

  • 21. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
    Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
    Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma.
    Feugier P; Filliatre-Clement L
    F1000Res; 2019; 8():. PubMed ID: 30906531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Follicular lymphoma: first - line selection criteria of treatment].
    Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
    Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Updates in treatment strategies for follicular lymphoma].
    Fukuhara N
    Rinsho Ketsueki; 2020; 61(9):1252-1258. PubMed ID: 33162523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.
    Bachy E; Rufibach K; Parreira J; Launonen A; Nielsen T; Hackshaw A
    Adv Ther; 2021 Jul; 38(7):3489-3505. PubMed ID: 34041708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
    Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
    Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
    Nastoupil LJ
    Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
    Jacobson CA; Freedman AS
    Curr Hematol Malig Rep; 2016 Jun; 11(3):218-23. PubMed ID: 26995595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
    Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
    Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
    Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Follicular lymphoma: recent advances].
    Ando K
    Rinsho Ketsueki; 2018; 59(10):2104-2108. PubMed ID: 30305515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
    Guzauskas GF; Masaquel A; Thuresson PO; Dawson K; Veenstra DL
    Leuk Lymphoma; 2019 Jul; 60(7):1668-1676. PubMed ID: 30632837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
    Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current standard treatments and future outlook for follicular lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2024; 65(9):1004-1011. PubMed ID: 39358254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-risk follicular lymphoma: Treatment options.
    Kahl B
    Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.